comprehensive -WSS

comprehensive

author：explore 2025-09-02 22:20:48 - browse：51

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Addiction doctors spar with methadone clinics over legislation

explore

WSS

Biohaven protein

Akili, maker of video game for ADHD, to be acquired for 34 million

Democrats decry new health bill for going easy on private equity

Heat waves linked to early deliveries, preterm births in new study

Former reverend arrested for allegedly killing 8

Senate panel puts off hardest PBM reforms for another day

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Heat waves linked to early deliveries, preterm births in new study

Apple is now the first public company to be valued at $3 trillion

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

How to save PrEP access — and even expand it

Senate panel puts off hardest PBM reforms for another day

Heart attack and stroke risk calculators need revising

Biohaven protein

Medicare proposal to cover medical devices draws a mixed reaction

UHS says company favors patients whose insurance pays more

hotspot

Rise in cancer among younger people worries and puzzles doctors

New Alzheimer's drugs heat up race for early detection blood tests

Former reverend arrested for allegedly killing 8

Search called off for baby washed away in Pennsylvania flash flood

STAT Report: Patient voices and perspectives

Antibiotic resistance nearly killed me, so I'm raising awareness of it

hotspot

explore

leisure time

explore